Mirati Therapeutics

115 articles with Mirati Therapeutics

• Mirati Therapeutics Announces The Appointment Of Maya Martinez-Davis To The Board Of Directors

  12/10/2018

  Mirati Therapeutics, Inc. today announced the appointment of Maya Martinez-Davis to the Company's Board of Directors, effective immediately.

• Mirati Therapeutics Announces FDA Clearance Of Investigational New Drug (IND) Application To Initiate Phase 1/2 Trial Of KRAS G12C Inhibitor, MRTX849

  11/29/2018

  Mirati Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared the company's investigational new drug (IND) application for MRTX849, a small molecule inhibitor of KRAS G12C.  Mirati is developing MRTX849 for the treatment of cancers driven by KRAS G12C mutations. 

• Mirati Therapeutics To Present At The 30th Annual Piper Jaffray Healthcare Conference

  11/20/2018

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will participate in a fireside chat at the 30th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, November 27th at 12:30 p.m. EST/ 9:30 a.m. PST. Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will represent Mirati at the conference.

• Mirati Presents Preliminary Biomarker Data From Ongoing Phase 2 Clinical Trial Of Sitravatinib In Combination With Nivolumab At The SITC 33rd Annual Meeting

  11/9/2018

  Mirati Therapeutics, Inc. announced preliminary biomarker data from the ongoing Phase 2 clinical trial of sitravatinib in combination with nivolumab (OPDIVO®) in non-small cell lung cancer (NSCLC) patients at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, D.C.

• Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting

  11/9/2018

  Mirati Therapeutics, Inc. announced data from the ongoing Phase 2 clinical trial of mocetinostat in combination with durvalumab (IMFINZI®) in non-small cell lung cancer (NSCLC) patients at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, D.C.

• Mirati Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of Sitravatinib In Combination With Anti-PD1 Antibody Tislelizumab In Patients With Advanced Solid Tumors

  11/8/2018

  Mirati Therapeutics, Inc. today announced dosing of the first patient under its collaboration agreement with BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) in a Phase 1b clinical trial to assess the safety and tolerability, pharmacokinetics and preliminary anti-tumor activity of Mirati's sitravatinib in combination with BeiGene's investigational anti-PD1 antibody, tislelizumab, in patients with advanced solid tumors.

• Mirati Therapeutics To Present At The 27th Annual Credit Suisse Healthcare Conference

  11/7/2018

  Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will present a corporate overview at the conference.

• Mirati Therapeutics Reports Third Quarter Financial Results

  11/6/2018

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2018

• Mirati To Present New Data In Ongoing Phase 2 Clinical Trials At The SITC 33rd Annual Meeting

  11/5/2018

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced that the Company will have two oral presentations at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting to be held November 9-11, 2018 in Washington, D.C.

• Mirati Therapeutics Announces Submission of IND Application for MRTX849, a KRAS G12C Inhibitor, to Treat Non-Small Cell Lung Cancer and Colorectal Cancer

  10/30/2018

  The trial will utilize an accelerated titration design with single patient cohorts and intra-patient dose escalation to rapidly achieve an active dose level for MRTX849.

• Mirati Therapeutics Presents Updated Positive Clinical Data From Sitravatinib Immuno-Oncology Combination Trial At ESMO 2018 Congress And Announces FDA Guidance For Registration Trial

  10/22/2018

  Updated analysis from ongoing Phase 2 trial of sitravatinib in combination with nivolumab demonstrated significant clinical activity in patients with checkpoint refractory non-small cell lung cancer (NSCLC)

• Mirati Therapeutics Announces Updated Data From Ongoing Clinical Trial Of Single Agent Sitravatinib At The 2018 ESMO Congress

  10/21/2018

  Clinical data in non-small cell lung cancer (NSCLC) and melanoma patients with CBL inactivating mutations treated with single agent sitravatinib demonstrate encouraging results

• Mirati Therapeutics To Provide Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress And Conduct Investor Call

  10/15/2018

  Two oral presentations will feature updated clinical data from an ongoing phase 2 clinical trial of sitravatinib in combination with nivolumab and a Phase 1b clinical trial of sitravatinib as a single agent

• Mirati Therapeutics To Participate In Oncology Panels At The 2018 Citi Biotech Conference

  8/29/2018

  Mirati Therapeutics, Inc. will participate in two panel discussions, at the 2018 Citi Biotech Conference in Boston. Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will represent Mirati at the event.

• Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition

  8/16/2018

  Mirati Therapeutics, Inc. announced that a KRAS G12C poster will be presented by scientists from Mirati and Array BioPharma at the 255th American Chemical Society (ACS) National Meeting & Exposition being held in Boston, MA, August 19-23, 2018.

• Mirati Therapeutics Reports 2018 Second Quarter Financial Results

  8/1/2018

  Mirati Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2018.

• Mirati Therapeutics To Present Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress

  7/24/2018

  Mirati Therapeutics, Inc. announced that two abstracts highlighting data from ongoing clinical studies of sitravatinib will be presented as Proffered Papers in oral presentations at the 2018 Annual Meeting of the European Society for Medical Oncology October 19-23 in Munich, Germany.

• Mirati Therapeutics Added to Russell 2000® Index

  6/25/2018

  Mirati Therapeutics, Inc. announced that it has been added to the Russell 2000® Index

• 

  Loncar Cancer Immunotherapy Index Reshuffles Listed Companies

  6/20/2018

  The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.

• Mirati Therapeutics Announces Closing of Public Offering of 3,162,500 Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

  6/11/2018

  Mirati Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 3,162,500 shares of its common stock at a public offering price of $38.85 per share